The state of New York currently has 48 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
06/24/2025
Locations: IMA Clinical Research Albany, Albany, New York +7 locations
Conditions: Alzheimer Disease
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
Recruiting
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Integrative Clinical Trials, Brooklyn, New York
Conditions: Alzheimer Disease
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/23/2025
Locations: SPRI, Brooklyn, New York +4 locations
Conditions: Early Alzheimers Disease
Early Age-Related Hearing Loss Investigation (EARHLI)
Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on reducing cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD).
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
06/21/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Alzheimer Disease, Hearing Loss, Cognitive Impairment
[18F]PI-2620 Phase 3 Histopathological Study
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2025
Locations: Velocity Clinical Research, East Syracuse, New York +1 locations
Conditions: Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
06/20/2025
Locations: Neurological Associates of Albany, PC, Albany, New York +2 locations
Conditions: Preclinical Alzheimer's Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2025
Locations: Local Institution - 1018, Manhasset, New York +4 locations
Conditions: Psychosis Associated With Alzheimer's Disease
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
Recruiting
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/19/2025
Locations: Alzheimer's Disease Research Center, Albany, New York
Conditions: Alzheimer Disease, Early Onset
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B wi... Read More
Gender:
ALL
Ages:
Between 55 years and 95 years
Trial Updated:
06/18/2025
Locations: Dent Neurologic Institute, Amherst, New York +2 locations
Conditions: Alzheimer's Disease Psychosis
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2025
Locations: Local Institution - 1231, Syracuse, New York +2 locations
Conditions: Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2025
Locations: Velocity Clinical Research, Syracuse ( Site 0125), East Syracuse, New York +1 locations
Conditions: Alzheimer Disease, Dementia
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Recruiting
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/16/2025
Locations: Local Institution - 0034, Buffalo, New York +2 locations
Conditions: Agitation, Alzheimer Disease